While the U.K.'s National Institute for Health and Care Excellence (NICE) recognizes the promise of CAR T therapies, it's balking at the price. In a draft guidance released Tuesday, NICE recommended against using Foster City, Calif.-based Gilead Sciences Inc.'s Yescarta (axicabtagene ciloleucel) to treat aggressive diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma because of its cost.